共 54 条
[1]
Bresalier R.S.(2005)Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092-1102
[2]
Sandler R.S.(2000)Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 1520-1528
[3]
Quan H.(2005)Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 365 475-481
[4]
Bombardier C.(2000)Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 1247-1255
[5]
Laine L.(2005)Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 1071-1080
[6]
Reicin A.(2006)APC and PreSAP Trial Investigators: Effect of celexocib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas Circulation 114 1028-1035
[7]
Graham D.J.(2003)Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 405-409
[8]
Campen D.(2003)Short-and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension Hypertension 42 310-315
[9]
Hui R.(2003)Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension Circulation 108 2 308-2 311
[10]
Silverstein F.E.(2004)Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells Biochem Pharmacol 68 341-350